Loading...
XKRX069620
Market cap987mUSD
Dec 24, Last price  
125,000.00KRW
1D
-0.71%
1Q
-10.78%
Jan 2017
81.95%
Name

Daewoong Pharma

Chart & Performance

D1W1MN
XKRX:069620 chart
P/E
12.90
P/S
1.05
EPS
9,690.50
Div Yield, %
0.46%
Shrs. gr., 5y
2.05%
Rev. gr., 5y
5.92%
Revenues
1.38t
+7.44%
400,443,393,000484,346,075,000548,326,626,000613,750,337,000509,993,136,000710,547,146,300669,013,832,880682,508,015,670735,889,423,940839,686,478,170883,920,424,600960,307,423,0401,031,427,425,5301,113,425,920,8801,055,423,690,0001,152,975,698,1701,280,091,851,0101,375,328,744,877
Net income
111.50b
+163.98%
48,523,054,00058,948,245,00032,930,963,00049,467,008,00017,562,830,00050,185,946,00034,079,293,66058,399,564,79031,544,474,83042,930,060,24026,969,821,26031,580,584,390-15,151,848,39022,005,927,02024,148,065,67024,505,735,56042,239,518,340111,501,799,110
CFO
132.57b
+12.14%
48,962,960,00025,810,021,00031,326,248,00093,907,855,00020,110,498,00078,822,880,64045,023,829,91054,157,051,36025,945,213,40035,887,836,00015,377,371,370103,938,172,74047,499,563,37057,600,275,950100,981,257,11039,994,278,510118,214,603,330132,568,693,210
Dividend
Dec 27, 2023600 KRW/sh
Earnings
Feb 03, 2025

Profile

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
URL
https://www.daewoong.co.kr/kr/main/index
IPO date
Nov 01, 2002
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,375,328,745
7.44%
1,280,091,851
11.03%
1,152,975,698
9.24%
Cost of revenue
1,085,146,292
1,050,152,118
950,699,300
Unusual Expense (Income)
NOPBT
290,182,453
229,939,733
202,276,399
NOPBT Margin
21.10%
17.96%
17.54%
Operating Taxes
129,444
(833,512)
(10,322,780)
Tax Rate
0.04%
NOPAT
290,053,009
230,773,245
212,599,179
Net income
111,501,799
163.98%
42,239,518
72.37%
24,505,736
1.48%
Dividends
(6,641,525)
(6,641,525)
(6,457,617)
Dividend yield
0.50%
0.38%
0.40%
Proceeds from repurchase of equity
49,889,893
181,200,437
BB yield
-3.74%
-11.13%
Debt
Debt current
370,385,455
234,855,580
256,974,365
Long-term debt
69,457,523
220,053,752
196,716,269
Deferred revenue
33,527,566
39,184,776
38,465,417
Other long-term liabilities
30,973,813
94,192,954
21,345,877
Net debt
9,774,402
205,623,113
259,414,032
Cash flow
Cash from operating activities
132,568,693
118,214,603
39,994,279
CAPEX
(109,337,876)
(113,308,833)
(74,794,323)
Cash from investing activities
(165,620,550)
(106,871,719)
(87,683,369)
Cash from financing activities
39,218,430
15,516,597
50,223,932
FCF
187,656,397
162,882,525
235,392,927
Balance
Cash
137,684,957
140,650,847
173,733,899
Long term investments
292,383,619
108,635,372
20,542,702
Excess cash
361,302,139
185,281,627
136,627,816
Stockholders' equity
821,779,528
1,131,167,659
1,060,798,567
Invested Capital
1,148,063,859
1,126,783,874
1,061,429,297
ROIC
25.50%
21.09%
20.53%
ROCE
19.16%
17.47%
16.83%
EV
Common stock shares outstanding
11,424
11,069
11,005
Price
116,800.00
-26.31%
158,500.00
7.09%
148,000.00
-10.30%
Market cap
1,334,365,832
-23.94%
1,754,469,468
7.72%
1,628,672,808
-7.43%
EV
1,489,118,018
2,093,298,206
2,016,927,728
EBITDA
332,883,130
269,634,397
243,159,840
EV/EBITDA
4.47
7.76
8.29
Interest
13,149,680
8,405,545
10,248,267
Interest/NOPBT
4.53%
3.66%
5.07%